NCT07025889 2025-06-18IBI343 Combined With Sintilimab Plus Chemotherapy in Gastric CancerRuijin HospitalPhase 1/2 Recruiting55 enrolled
NCT05218889 2024-12-31Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic CancerChinese PLA General HospitalPhase 1/2 Recruiting90 enrolled